List of Excipients in Branded Drug METROCREAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Galderma Laboratories LP	METROCREAM	metronidazole	0299-3836	BENZYL ALCOHOL
Galderma Laboratories LP	METROCREAM	metronidazole	0299-3836	GLYCERIN
Galderma Laboratories LP	METROCREAM	metronidazole	0299-3836	ISOPROPYL PALMITATE
Galderma Laboratories LP	METROCREAM	metronidazole	0299-3836	LACTIC ACID
Galderma Laboratories LP	METROCREAM	metronidazole	0299-3836	SODIUM HYDROXIDE
Galderma Laboratories LP	METROCREAM	metronidazole	0299-3836	SORBITOL
Galderma Laboratories LP	METROCREAM	metronidazole	0299-3836	WATER

METROCREAM Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

METROCREAM is a metronidazole 0.75% topical cream for the treatment of inflammatory lesions associated with rosacea. Its commercial opportunity is driven less by active-ingredient differentiation than by formulation performance, tolerability, preservative strategy, packaging, and generic substitution economics. The most attractive development paths are a lower-irritation cream, a preservative-reduced or preservative-free presentation, an optimized emulsion with improved sensory properties, and a differentiated pump or unit-dose package.

What is METROCREAM and how is it formulated?

METROCREAM contains metronidazole at 0.75% w/w in a topical oil-in-water cream. The reference product is intended for cutaneous use in rosacea and is applied to affected areas as directed by the prescribing information.[1]

The labeled inactive ingredients include a conventional emulsion system with fatty alcohols, emollients, surfactants, humectants, water, pH adjusters, and preservatives. Public product labeling identifies excipients including benzyl alcohol, cetyl alcohol, glycerin, glyceryl stearate, isopropyl myristate, methylparaben, PEG-100 stearate, purified water, sodium hydroxide, stearyl alcohol, and sorbitan monostearate.[1,2]

Formulation function	METROCREAM excipient examples	Commercial role
Aqueous vehicle	Purified water	Provides the continuous phase
Emolliency	Isopropyl myristate, stearyl alcohol, cetyl alcohol	Controls spreadability, after-feel, and moisturization
Emulsion structure	Glyceryl stearate, PEG-100 stearate, sorbitan monostearate	Stabilizes the cream and controls viscosity
Humectancy	Glycerin	Supports hydration and skin feel
Preservation	Benzyl alcohol, methylparaben	Controls microbial growth
pH adjustment	Sodium hydroxide	Establishes formulation pH and supports stability
Texture and viscosity	Cetyl alcohol, stearyl alcohol, glyceryl stearate	Controls rheology and application characteristics

The formulation is technically conventional. That creates a relatively accessible generic-development pathway but leaves room for differentiation through excipient selection and delivery design.

What excipients are most important in METROCREAM?

Benzyl alcohol and methylparaben

The preservative system is a central commercial issue. Benzyl alcohol can contribute to odor and local irritation in susceptible users. Methylparaben is widely used and generally effective, but preservative perception remains relevant in dermatology, particularly for patients with sensitive or compromised skin.

A developer could pursue three strategies:

1. Retain the reference preservative system for a lower-cost, conventional generic.
2. Replace methylparaben or benzyl alcohol with an alternative system supported by preservative-effectiveness testing.
3. Develop a preservative-free multidose system using an airless pump, metered-dose container, or unit-dose sachet.

A preservative-free presentation would require control of microbial risk through container design, manufacturing controls, water activity, formulation pH, and in-use stability. It would also need to demonstrate that the package maintains dose delivery throughout the labeled period.

Glyceryl stearate, PEG-100 stearate, and sorbitan monostearate

These excipients create the cream’s emulsion structure. Their ratios influence:

• Droplet size and physical stability
• Viscosity
• Rub-in time
• Whitening after application
• Residue and tack
• Compatibility with the metronidazole drug substance
• Product release from the vehicle

A Q1/Q2 generic would typically seek close qualitative and quantitative alignment with the reference product. A 505(b)(2) product could use a different emulsifier system if the sponsor can support the alternative formulation, clinical rationale, and product performance.

Isopropyl myristate

Isopropyl myristate improves spreadability and reduces the drag associated with high-fatty-alcohol creams. It can also affect active-ingredient partitioning between the vehicle and skin.

Its commercial value is linked to sensory performance. A cream that spreads rapidly, leaves less residue, and does not pill under sunscreen or cosmetics may generate better adherence even without changing the active ingredient.

The excipient also requires careful evaluation for irritation, comedogenicity, oxidation, and interaction with packaging components.

Cetyl alcohol and stearyl alcohol

These fatty alcohols act as consistency agents, co-emulsifiers, and emollients. Their concentration affects viscosity and the product’s melting and spreading profile.

Reducing fatty alcohol content can produce a lighter cream but may reduce physical stability. Increasing it can improve body and occlusivity while increasing drag and residue. This creates an optimization opportunity for a “light cream” positioned between a conventional cream and a gel.

Glycerin

Glycerin supports hydration and can improve the feel of a topical product on dry or irritated skin. Excessive glycerin can increase tackiness, particularly in warm or humid conditions.

A development program should test glycerin concentration against:

• Skin hydration
• Tack
• Drying time
• Rub-out
• Compatibility with the preservative system
• Patient preference

What formulation opportunities exist for METROCREAM?

Can a low-irritation METROCREAM generic be developed?

Yes. A lower-irritation product could retain metronidazole 0.75% while modifying the excipient system. The strongest design targets are:

• Reduced or eliminated benzyl alcohol
• Reduced surfactant burden
• Lower residual alkalinity
• Optimized pH
• Lower fragrance or odor contribution
• Improved emollient balance
• Reduced rubbing requirement
• Preservative-free packaging where feasible

The formulation must preserve metronidazole solubilization, physical stability, microbial quality, and dose uniformity. A change that improves tolerability but reduces chemical stability would not create a viable product.

Can a preservative-free cream compete with METROCREAM?

A preservative-free cream could command a premium if it offers a credible tolerability or packaging benefit. The commercial case is stronger for:

• Patients with sensitive skin
• Long-term rosacea treatment
• Patients using several topical products
• Dermatology practices emphasizing barrier care
• Cash-pay or specialty-pharmacy channels

The primary barrier is packaging cost. Airless pumps and unit-dose systems increase component costs and may require new filling equipment. A preservative-free product also faces greater scrutiny over microbial control and in-use performance.

Is a gel or lotion a direct substitute?

A gel or lotion can compete therapeutically but may not be an interchangeable generic substitute for a cream. Dosage form differences affect formulation requirements, product labeling, regulatory pathway, and substitution status.

A lotion may offer improved spreadability and less residue. A gel may dry faster but can be more irritating if it contains alcohol or a high level of propylene glycol. A cream remains better positioned for patients seeking moisturization and reduced dryness.

What FDA regulatory pathway applies to METROCREAM?

The principal pathway for a conventional generic is an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements applicable to topical products.[3]

For a metronidazole topical cream, the development package typically addresses:

Regulatory element	Key requirement
Active ingredient	Metronidazole at the labeled strength
Dosage form	Cream
Route	Topical cutaneous
Pharmaceutical equivalence	Same active ingredient, strength, dosage form, and route
Product quality	Assay, impurities, microbial limits, viscosity, pH, particle or droplet characteristics where applicable
Stability	Long-term and accelerated stability in the proposed container
Bioequivalence	FDA-recognized approach for the specific topical product
Labeling	Reference-listed-drug labeling, subject to permitted generic changes
Packaging	Demonstrated protection, compatibility, and dose delivery

FDA’s product-specific guidance and current topical bioequivalence standards control the required evidence. The inactive ingredient database can help identify excipients previously used in approved products, but it does not by itself establish acceptability for a new formulation.[4]

A 505(b)(2) application may be relevant for a materially different cream, preservative-free product, novel package, or altered delivery system that cannot rely fully on the reference product’s safety and efficacy findings.

What patents and exclusivities protect METROCREAM?

METROCREAM is an old small-molecule topical product. Its core composition and use patents, if any, are unlikely to provide a durable barrier comparable to those associated with newer branded dermatology products. Commercial freedom-to-operate analysis should focus on current Orange Book listings, issued formulation patents, packaging claims, and any patent rights covering modified topical delivery systems.[5]

Protection category	Relevance to METROCREAM
Active-ingredient patent	Metronidazole is a long-established generic compound
Original product patent	Any original product claims are likely expired or commercially weak
Composition patent	May apply to a specific cream vehicle or excipient ratio
Method-of-use patent	Could cover rosacea treatment or a defined dosing regimen, subject to validity and expiration
Packaging patent	Could affect airless, metered-dose, or unit-dose systems
Regulatory exclusivity	Not expected to provide a current barrier for an old topical product
Trade secret	Manufacturing process parameters, emulsion order, and scale-up controls may remain valuable

A sponsor should not assume that the absence of a visible active-ingredient patent eliminates risk. Formulation and device patents can remain relevant, especially for premium products using proprietary packaging or a specialized preservative-free system.

When does METROCREAM lose exclusivity?

The principal exclusivity risk for METROCREAM has already shifted from patent expiry to generic competition and product-level differentiation. The commercial question is whether a new applicant can obtain approval for a pharmaceutically equivalent cream and enter without infringing any unexpired listed patent.

For an ANDA applicant, a Paragraph IV certification may be required if the reference product has an unexpired Orange Book-listed patent. A Paragraph IV filing can trigger patent litigation under 21 U.S.C. § 355(j), potentially creating a 30-month stay of approval if the patent holder sues within the statutory period.[6]

For a legacy topical product, the highest-probability scenario is approval based on non-infringement or expiration certifications rather than prolonged litigation. The specific Orange Book status must be evaluated against the current FDA listing and the applicant’s filing date.

What is the Orange Book status of METROCREAM?

The FDA Orange Book identifies reference-listed drugs, approved dosage forms, and applicable patent and exclusivity information.[5] METROCREAM should be assessed under its NDA and dosage-form listing rather than by searching metronidazole products as a group.

The relevant review should confirm:

• Current marketing status of the reference product
• NDA number and strength
• Whether the cream remains listed as the reference product
• Any unexpired listed patents
• Any pediatric or other regulatory exclusivity
• Approved generic versions
• Whether an ANDA applicant may rely on a suitability petition or must file a different application

MetroCream, MetroGel, and metronidazole lotion products should not be treated as interchangeable regulatory references. Different dosage forms can have separate ANDA pathways and distinct bioequivalence requirements.

Which companies are competing in topical metronidazole?

Competition exists across creams, gels, lotions, and branded rosacea products. The relevant competitive groups are:

Generic manufacturers

Generic dermatology companies can compete through low acquisition cost, wholesaler coverage, and pharmacy substitution. Their main advantage is scale and existing topical manufacturing capability.

Branded dermatology companies

Branded products compete through tolerability claims, packaging, patient support, physician familiarity, and channel control. A branded metronidazole cream can remain commercially relevant if it reduces irritation or improves adherence, even when generic metronidazole is available.

Specialty dermatology platforms

Companies with rosacea portfolios can bundle topical metronidazole with ivermectin, azelaic acid, brimonidine, oxymetazoline, or barrier-support products. This strategy increases prescriber and payer leverage but also exposes the product to substitution within the treatment class.

What commercial opportunities exist for METROCREAM excipients?

Premium sensitive-skin cream

A premium formulation could use a reduced-irritant excipient system with a richer but non-greasy sensory profile. The target customer is the patient requiring long-term rosacea management who is dissatisfied with burning, dryness, residue, or incompatibility with cosmetics.

Potential claims would need regulatory support and careful wording. Claims such as “preservative-free,” “fragrance-free,” or “non-comedogenic” require documented formulation and testing support.

Airless-pump presentation

An airless pump can reduce exposure to environmental contamination and support a preservative-reduced formulation. It can also improve hygiene compared with a jar and provide a more modern patient experience.

The risks include:

• Higher packaging cost
• Priming and residual-volume issues
• Dose variability near container exhaustion
• Compatibility with the cream’s viscosity
• Component supply constraints
• Device-related regulatory requirements

Unit-dose sachets

Unit-dose packaging is attractive for samples, adherence programs, travel, and controlled dosing. It is less attractive for chronic daily use because of packaging waste and higher cost per dose.

Pharmacy-compounding and institutional supply

A standardized excipient platform could support contract manufacturing or pharmacy-compounding channels. This opportunity is smaller than the commercial generic market but may appeal to dermatology networks seeking a formulation without a specific preservative or with a customized sensory profile.

Global formulation platform

A common metronidazole cream platform could be adapted for regional excipient requirements, container standards, and preservative restrictions. Geographic expansion is most efficient where the product can qualify through a reliance or abbreviated registration pathway.

How strong is the METROCREAM patent estate?

The patent estate is likely weak around the metronidazole molecule and conventional cream concept. Its potential strength is higher around narrowly drafted formulation, packaging, manufacturing, or delivery claims.

Estate component	Strategic strength
Metronidazole composition	Low
Conventional 0.75% cream	Low to moderate, depending on surviving claims
Specific excipient ratio	Moderate if claims are narrow and technically supported
Preservative-free system	Moderate if combined with package and stability limitations
Airless delivery system	Moderate, usually dependent on device claims
Manufacturing process	Moderate as a trade secret; variable as a patent
Method of treating rosacea	Usually limited by prior art and claim scope

For a new entrant, the preferred strategy is to avoid unnecessary dependence on the exact branded vehicle while maintaining the required performance profile. A distinct excipient architecture can reduce formulation overlap, but it may also increase regulatory development cost.

What generic launch scenarios exist for METROCREAM?

Low-cost conventional generic

This product closely matches the reference cream and competes on price, wholesaler access, and substitution. It has the fastest route to commercial relevance but the lowest differentiation.

Formulation-improved generic

This product retains metronidazole 0.75% but improves rub-in, residue, odor, preservative burden, or packaging. It may require greater development work and potentially a more complex regulatory pathway.

Premium dermatology product

This product uses a differentiated cream, airless pump, or patient-support model. Its economics depend on payer coverage, physician preference, and the ability to sustain a price premium after generic entry.

Combination or line-extension strategy

A sponsor could pair the cream with other rosacea products or launch adjacent dosage forms. This expands the franchise but introduces additional regulatory, clinical, and commercial costs.

What manufacturing and excipient barriers affect commercialization?

The main manufacturing barriers are process control and scale-up rather than raw-material scarcity. Critical parameters include:

• Order and temperature of phase addition
• Homogenization intensity
• Cooling rate
• Emulsion droplet size
• pH adjustment sequence
• Active-ingredient incorporation
• Air entrapment
• Bulk hold time
• Filling temperature
• Container compatibility

Excipient suppliers can also affect continuity. PEG-100 stearate, glyceryl stearate, fatty alcohols, preservatives, and specialty packaging components may have multiple grades with different impurity profiles and performance characteristics.

A robust commercial formulation should qualify at least two sources for critical excipients where feasible. Changes in fatty alcohol purity, surfactant composition, or preservative grade can alter viscosity, microbial protection, and release performance.

Key Takeaways

• METROCREAM is a metronidazole 0.75% topical cream for rosacea.
• Its excipient system is a conventional emulsion built around fatty alcohols, glyceryl stearate, PEG-100 stearate, sorbitan monostearate, glycerin, isopropyl myristate, water, and preservatives.
• The strongest product opportunities are lower-irritation, preservative-reduced, preservative-free, airless-pump, and improved-sensory formulations.
• Conventional generic entry is likely to compete primarily on price and distribution.
• A differentiated cream may support premium positioning but can require a 505(b)(2) strategy, greater clinical support, or more extensive product-performance evidence.
• Current Orange Book listings, patents, exclusivities, and reference-product status must control any Paragraph IV or freedom-to-operate decision.
• Manufacturing know-how in emulsion processing, preservative control, filling, and packaging is more commercially important than the old metronidazole molecule.

FAQs

Is METROCREAM the same as metronidazole gel?

No. Both may contain metronidazole, but cream and gel are different dosage forms with different excipient systems, sensory properties, regulatory references, and potential substitution rules.

Can benzyl alcohol be removed from a METROCREAM generic?

Yes, but removal changes preservation, stability, solubility, and local-tolerability profiles. The replacement strategy must be supported by microbial effectiveness, stability, and product-performance data.

Does a preservative-free metronidazole cream require new clinical trials?

Not necessarily. The required evidence depends on the regulatory pathway, formulation differences, product claims, and FDA’s applicable bioequivalence standards. A materially different formulation may require more than a conventional ANDA approach.

Is an airless pump patentable for metronidazole cream?

The pump alone may not create strong patent protection. Patentability is more likely to depend on a technically specific combination involving the cream composition, package, dose delivery, microbial control, or stability performance.

What is the best excipient strategy for a premium rosacea product?

The strongest commercial strategy is generally a low-irritation, low-residue cream with a validated preservative-reduced or preservative-free package, strong cosmetic compatibility, and consistent dose delivery.

References

1. DailyMed. (n.d.). METROCREAM: Metronidazole cream, 0.75% prescribing information. U.S. National Library of Medicine.

2. Galderma Laboratories, L.P. (n.d.). MetroCream metronidazole cream, 0.75% product labeling. U.S. Food and Drug Administration labeling repository.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredient

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-amendments-implementation-fda-relevant-guidance-anda-submissions